A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis

Using cell-based assay (CBA) blood testing, 18.7% of 635 patients who did not have prior antibodies were  positive for Lrp4 antibodies. They developed a test to detect these antibodies and found that around 18.7% of these patients had LRP4 antibodies, with variations across different populations. Some patients had both LRP4 antibodies and other MG-related antibodies, and they tended to have more severe symptoms. The characteristics and treatment response of LRP4-positive patients were more similar to those with a different type of MG called AChR-positive MG, rather than MuSK-positive MG.